Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2014-02-13 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于公司及相关主体承诺履行情况的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Xintai Pharmaceutical Co., Ltd. regarding the fulfillment status of commitments made by the company and related parties, including shareholders and actual controllers. It references regulatory guidelines from the China Securities Regulatory Commission (CSRC) about commitments and their fulfillment. The content focuses on the status of share lock-up commitments and avoidance of competition commitments, with no financial statements or report data included. The document length is 2603 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication of financial results, audit opinions, or management discussion of financial performance. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory compliance announcement about commitment fulfillment, not a financial report or other specific filing type.
2014-02-13 Chinese
关于收购深圳市健善康医药有限公司股权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the acquisition of 100% equity in Shenzhen Jiankang Pharmaceutical Co., Ltd. by Shenzhen Xintai Pharmaceutical Co., Ltd. It details the transaction terms, parties involved, financial figures of the target company, and the impact on the acquirer. There is no indication that this is a full financial report, audit report, or regulatory filing. The document is a specific announcement about a capital transaction (equity acquisition) and financing activity. It does not contain financial statements or detailed financial analysis but focuses on the acquisition event and its terms. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 2625 characters, which is consistent with an announcement rather than a full report.
2014-01-22 Chinese
关于监事会主席李忠先生逝世的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the death of the chairman of the supervisory board (监事会主席) of the company. It includes condolences and information about the temporary reduction in the number of supervisors and plans to fill the vacancy. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no mention of shareholder votes or meetings. This is a management or board-related announcement about a change in senior personnel due to death. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS.
2014-01-09 Chinese
关于获得阿利沙坦酯片生产批件的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the receipt of a production approval for a new drug (Alisartan Isoproxil tablets) from the Guangdong Food and Drug Administration. It includes details about the drug approval numbers and emphasizes the positive impact on the company's future performance. The document is only 600 characters long and does not contain any financial statements, detailed financial data, or comprehensive report content. It is an official announcement about a regulatory approval related to the company's product, not a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2013-10-24 Chinese
关于签订研发技术转让协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the signing of a research and development technology transfer agreement. It details the transaction terms, parties involved, and the impact on the company. The text is about a specific transaction involving technology transfer and licensing rights, including financial terms and risk disclosures. It is not a financial report, earnings release, or management discussion. It is a formal announcement of a capital transaction related to technology acquisition and licensing. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on a financing-related transaction (technology transfer agreement with payment terms). The document length is 2429 characters, which is relatively short but contains substantive transaction details, not just a brief notice or report publication announcement.
2013-10-23 Chinese
关于使用自有闲置资金投资银行理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's decision to invest idle funds in bank wealth management products. It details the investment plan, risk assessment, and approvals from the board and supervisory committee. There are no financial statements or comprehensive financial data presented. The document is relatively short (3347 characters) and serves as a disclosure of a financing-related activity rather than a full financial report or earnings release. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is best classified as a Capital/Financing Update (CAP) because it informs about the company's use of capital for investment purposes.
2013-10-21 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.